Compare NBIX & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NBIX | RDY |
|---|---|---|
| Founded | 1992 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 11.6B |
| IPO Year | 1996 | 2001 |
| Metric | NBIX | RDY |
|---|---|---|
| Price | $130.61 | $13.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 22 | 1 |
| Target Price | ★ $180.82 | $16.90 |
| AVG Volume (30 Days) | 901.1K | ★ 2.1M |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 0.54% |
| EPS Growth | ★ 41.95 | N/A |
| EPS | ★ 4.67 | N/A |
| Revenue | ★ $161,626,000.00 | N/A |
| Revenue This Year | $22.85 | $7.81 |
| Revenue Next Year | $10.36 | $3.20 |
| P/E Ratio | $27.09 | ★ $18.67 |
| Revenue Growth | ★ 977.51 | N/A |
| 52 Week Low | $97.30 | $12.82 |
| 52 Week High | $160.18 | $16.17 |
| Indicator | NBIX | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 50.14 | 39.30 |
| Support Level | $124.29 | $12.93 |
| Resistance Level | $136.23 | $14.14 |
| Average True Range (ATR) | 4.29 | 0.23 |
| MACD | -0.08 | -0.02 |
| Stochastic Oscillator | 59.64 | 26.75 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.